AU2011326732B2 - Skin permeating and cell entering (space) peptides and methods of use thereof - Google Patents

Skin permeating and cell entering (space) peptides and methods of use thereof

Info

Publication number
AU2011326732B2
AU2011326732B2 AU2011326732A AU2011326732A AU2011326732B2 AU 2011326732 B2 AU2011326732 B2 AU 2011326732B2 AU 2011326732 A AU2011326732 A AU 2011326732A AU 2011326732 A AU2011326732 A AU 2011326732A AU 2011326732 B2 AU2011326732 B2 AU 2011326732B2
Authority
AU
Australia
Prior art keywords
seq
peptide
composition
sirna
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2011326732A
Other languages
English (en)
Other versions
AU2011326732A1 (en
Inventor
Tracy Hsu
Samir M. Mitragotri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2011326732A1 publication Critical patent/AU2011326732A1/en
Application granted granted Critical
Publication of AU2011326732B2 publication Critical patent/AU2011326732B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2011326732A 2010-11-09 2011-10-05 Skin permeating and cell entering (space) peptides and methods of use thereof Expired - Fee Related AU2011326732B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41188410P 2010-11-09 2010-11-09
US61/411,884 2010-11-09
US201161527574P 2011-08-25 2011-08-25
US61/527,574 2011-08-25
US201161528036P 2011-08-26 2011-08-26
US61/528,036 2011-08-26
PCT/US2011/054967 WO2012064429A2 (en) 2010-11-09 2011-10-05 Skin permeating and cell entering (space) peptides and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2011326732A1 AU2011326732A1 (en) 2013-05-02
AU2011326732B2 true AU2011326732B2 (en) 2016-07-21

Family

ID=46051476

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011326732A Expired - Fee Related AU2011326732B2 (en) 2010-11-09 2011-10-05 Skin permeating and cell entering (space) peptides and methods of use thereof

Country Status (8)

Country Link
US (4) US8518871B2 (enExample)
EP (1) EP2638162B1 (enExample)
JP (1) JP2014500867A (enExample)
KR (1) KR20130139254A (enExample)
CN (1) CN103201386A (enExample)
AU (1) AU2011326732B2 (enExample)
CA (1) CA2811113A1 (enExample)
WO (1) WO2012064429A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8834423B2 (en) 2009-10-23 2014-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CA2811113A1 (en) 2010-11-09 2012-05-18 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013112488A2 (en) * 2012-01-23 2013-08-01 Kythera Biopharmaceuticals, Inc. Dermal filling compositions and methods
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
HK1209658A1 (en) 2012-05-01 2016-04-08 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Tip-loaded microneedle arrays for transdermal insertion
AU2013262972A1 (en) * 2012-05-16 2014-12-11 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
KR101329411B1 (ko) 2012-05-31 2013-11-14 주식회사 엘지생활건강 피부투과성 펩타이드
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
CN103897043A (zh) * 2012-12-28 2014-07-02 天津药物研究院 一种穿膜多肽连接拉帕替尼的制备及应用
US20140227174A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use therefor
WO2014123543A2 (en) * 2013-02-11 2014-08-14 Convoy Therapeutics Skin permeating and cell entering (space) peptides and methods of use therefor
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9642895B2 (en) 2013-08-12 2017-05-09 3M Innovative Properties Company Peptides for enhancing transdermal delivery
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
KR101608131B1 (ko) * 2013-11-14 2016-03-31 주식회사 엘지생활건강 인간 성장호르몬의 융합단백질을 포함하는 피부개선용 화장료 조성물
US9321821B2 (en) 2013-11-14 2016-04-26 Lg Household & Health Care Ltd. Cosmetic composition for improving skin conditions comprising fusion protein
WO2016033314A1 (en) * 2014-08-27 2016-03-03 The Regents Of The University Of California Skin penetrating peptides (spps) and methods of use therefor
EP3197920B1 (en) 2014-09-25 2021-01-13 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
WO2016071814A1 (en) 2014-11-04 2016-05-12 Università Degli Studi Di Milano A promoter for cutaneous absorption of active ingredients having peptidic structure
WO2016149673A1 (en) 2015-03-18 2016-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bioactive components conjugated to substrates of microneedle arrays
CN108350030B (zh) * 2015-09-10 2022-12-13 汉阳大学校产学协力团 皮肤可渗透肽及其使用方法
WO2017043920A1 (ko) * 2015-09-10 2017-03-16 한양대학교 산학협력단 피부 투과성 펩티드 및 그 이용방법
US20180251495A1 (en) * 2015-09-15 2018-09-06 The Regents Of The University Of California Skin-Penetrating Peptides and Compositions and Methods of Use Thereof
WO2017066768A1 (en) 2015-10-16 2017-04-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices
CA3002786C (en) * 2015-10-30 2021-09-07 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene
WO2017082690A1 (ko) * 2015-11-12 2017-05-18 주식회사 펩트론 미백, 피부 탄력, 주름 개선 및 상처치유 활성을 갖는 다기능성 피부투과 펩타이드
US11744889B2 (en) 2016-01-05 2023-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Skin microenvironment targeted delivery for promoting immune and other responses
CN105504066A (zh) * 2016-01-16 2016-04-20 广州市科玮生物技术有限公司 一种融合蛋白在化妆品中的应用
WO2017127834A1 (en) * 2016-01-23 2017-07-27 Sand Bruce J Enhanced transdermal delivery of active agents
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
KR20200042440A (ko) * 2017-04-17 2020-04-23 앰퍼샌드 바이오파마슈티컬스, 엘엘씨 고형종양, 과다색소침착 및 통풍의 전이를 억제하기 위한 완충제의 비경구 비전신적 투여
KR102083976B1 (ko) * 2017-12-18 2020-03-03 주식회사 엘지생활건강 혈관내피세포 성장인자의 융합 단백질을 포함하는 피부개선용 화장료 조성물
KR102083978B1 (ko) * 2017-12-18 2020-03-03 주식회사 엘지생활건강 혈소판유래 성장인자 a서브유닛의 융합 단백질을 포함하는 피부개선용 화장료 조성물
US12337000B2 (en) 2017-07-13 2025-06-24 Michael David FORREST Therapeutic modulators of the reverse mode of ATP synthase
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
US10905738B2 (en) 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
BR112021020951A2 (pt) 2019-04-19 2021-12-14 Fount Bio Inc Dispensação e retenção de agentes ativos dentro da pele
WO2020232394A1 (en) 2019-05-16 2020-11-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery
WO2021113410A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
KR102301572B1 (ko) * 2020-02-06 2021-09-10 인천대학교 산학협력단 신규한 핵산 분자 전달용 조성물 및 그 용도
CN113943778A (zh) * 2020-07-17 2022-01-18 通用电气医疗集团股份有限公司 用于核酸检测的分子探针及其制备方法和用途
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
EP4281034A1 (en) 2021-01-24 2023-11-29 Forrest, Michael, David Inhibitors of atp synthase - cosmetic and therapeutic uses
CN114315960B (zh) * 2021-12-31 2022-10-14 深圳市维琪医药研发有限公司 一种经修饰的肽及其美容组合物或药用组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US6083539A (en) 1994-12-16 2000-07-04 Sakuma Ebisu Kabushiki Kaisha Buckwheat starch syrup, method for preparing the same, and foods containing the same
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US20090070897A1 (en) 2006-01-12 2009-03-12 Goldman Barry S Genes and uses for plant improvement
JP4596391B2 (ja) * 2005-02-10 2010-12-08 国立大学法人大阪大学 細胞透過性ペプチド
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US7659252B2 (en) 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
JP2007143454A (ja) * 2005-11-25 2007-06-14 Toray Ind Inc 細胞膜通過性ペプチド
AU2006325030B2 (en) * 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
GB0606415D0 (en) 2006-03-31 2006-05-10 Univ Southampton Topical drug delivery
US20080213377A1 (en) 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
JP2008200011A (ja) * 2007-02-22 2008-09-04 Toray Ind Inc 細胞内移行性ペプチド、それを含有する医薬組成物及びその使用方法
AU2008295509A1 (en) 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US20110212028A1 (en) * 2008-09-16 2011-09-01 Kariem Ahmed Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds
US8389481B2 (en) * 2008-11-12 2013-03-05 University Of Medicine And Dentistry Of New Jersey Glutamate-enhanced cell-penetrating peptides and methods of using same
CN101812439B (zh) * 2009-02-25 2012-07-04 张舒羽 一种透皮结构域及其衍生的具有透皮作用的融合蛋白和其制备方法
WO2010123971A2 (en) * 2009-04-22 2010-10-28 Board Of Regents, The University Of Texas System Hydrogels for combinatorial delivery of immune-modulating biomolecules
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
CA2811113A1 (en) * 2010-11-09 2012-05-18 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hsu. T. et al. "Peptides as penetrating enhancers for transdermal drug delivery", 1 January 2009 Retrieved from the Internet: URL: http://abstracts.aaps.org/SecureView/AAPSJournal/sp6yz1fquaxu58xv5jdq.pdf *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Also Published As

Publication number Publication date
US20140161871A1 (en) 2014-06-12
WO2012064429A2 (en) 2012-05-18
KR20130139254A (ko) 2013-12-20
CA2811113A1 (en) 2012-05-18
WO2012064429A3 (en) 2012-08-02
US20170173173A1 (en) 2017-06-22
JP2014500867A (ja) 2014-01-16
CN103201386A (zh) 2013-07-10
EP2638162A4 (en) 2014-05-28
US9441014B2 (en) 2016-09-13
EP2638162A2 (en) 2013-09-18
AU2011326732A1 (en) 2013-05-02
EP2638162B1 (en) 2016-08-10
US8791062B2 (en) 2014-07-29
US20150025221A1 (en) 2015-01-22
US8518871B2 (en) 2013-08-27
US20120128756A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
AU2011326732B2 (en) Skin permeating and cell entering (space) peptides and methods of use thereof
Shi et al. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma
EP4305055A1 (en) Lipid vesicle-mediated delivery to cells
JP5721729B2 (ja) 活性産生送達分子
EP3597223A1 (en) Peptides for use as cell-penetrating peptides
US20180251495A1 (en) Skin-Penetrating Peptides and Compositions and Methods of Use Thereof
US10611796B2 (en) Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
US20140227174A1 (en) Skin permeating and cell entering (space) peptides and methods of use therefor
WO2014123543A2 (en) Skin permeating and cell entering (space) peptides and methods of use therefor
US20170258930A1 (en) Skin penetrating peptides (spps) and methods of use therefor
US20220175819A1 (en) Delivery and retention of active agents within the skin
US9526791B2 (en) Weakly acidic pH-responsive peptide and liposome containing same
US20250332275A1 (en) Branched Polypeptide Carrier for Efficient Nucleic Acid Delivery and Its Variants
JP2025521199A (ja) 有効成分の標的送達のための脂質マイクロバブル
EP2108698A1 (en) Vascular endothelial cell-binding peptide
HK1187074A (en) Skin permeating and cell entering (space) peptides and methods of use thereof
JP2008031142A (ja) 脂肪組織標的化ペプチド及び該ペプチドを有するリポソーム
CN120303001A (zh) 新型细胞穿透肽及其用途
HK1121683A (en) Method and carrier complexes for delivering molecules to cells
HK1089450B (en) Method and carrier complexes for delivering molecules to cells
HK1089450A1 (zh) 将分子递送到细胞的方法和载体复合物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 JUL 2016 .

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application